Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Pavlovsky

Showing results (61-70 of 75) with videos related to

Pageof 8
Sort By:
Cancer Immunology, Immunotherapy : CII|September 1, 2021
Venetoclax-resistant CLL cells show a highly activated and proliferative phenotypeEsteban Enrique Elias, Valeria Judith Sarapura Martinez, Mikele Amondarain, et al.
Biorxiv : the Preprint Server for Biology|February 17, 2023
Subdural CMOS optical probe (SCOPe) for bidirectional neural interfacingEric H Pollmann, Heyu Yin, Ilke Uguz, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 11, 2011
Molecular monitoring of imatinib in chronic myeloid leukemia patients in complete cytogenetic remission: does achievement of a stable major molecular response at any time point identify a privileged group of patients? A multicenter experience in Argentina and UruguayCarolina Pavlovsky, Isabel Giere, Beatriz Moiraghi, et al.
Journal of Medicinal Chemistry|June 29, 2001
4-Hydroxy-5,6-dihydropyrones as inhibitors of HIV protease: the effect of heterocyclic substituents at C-6 on antiviral potency and pharmacokinetic parametersS E Hagen, J Domagala, C Gajda, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 16, 2023
Long-Term Follow-Up in Patients With Chronic Myeloid Leukemia Treated With Ponatinib in a Real-World Cohort: Safety and Efficacy AnalysisMaría José Mela Osorio, Beatriz Moiraghi, María Victoria Osycka, et al.
Bioorganic & Medicinal Chemistry|September 1, 1996
Discovery and optimization of nonpeptide HIV-1 protease inhibitorsP J Tummino, J V Prasad, D Ferguson, et al.
British Journal of Haematology|October 6, 2004
Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the 'cutaneous variant'Andrés J M Ferreri, Elías Campo, John F Seymour, et al.
Journal of Medicinal Chemistry|November 26, 1997
4-hydroxy-5,6-dihydropyrones. 2. Potent non-peptide inhibitors of HIV proteaseB D Tait, S Hagen, J Domagala, et al.
Leukemia & Lymphoma|August 9, 2020
Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphomaGraeme A M Fraser, Asher Chanan-Khan, Fatih Demirkan, et al.
Leukemia|October 14, 2018
Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphomaG Fraser, P Cramer, F Demirkan, et al.
Pageof 8

Showing results (61-70 of 75) with videos related to

Sort By:
Pageof 8
Cancer Immunology, Immunotherapy : CII|September 1, 2021
Venetoclax-resistant CLL cells show a highly activated and proliferative phenotypeEsteban Enrique Elias, Valeria Judith Sarapura Martinez, Mikele Amondarain, et al.
Biorxiv : the Preprint Server for Biology|February 17, 2023
Subdural CMOS optical probe (SCOPe) for bidirectional neural interfacingEric H Pollmann, Heyu Yin, Ilke Uguz, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 11, 2011
Molecular monitoring of imatinib in chronic myeloid leukemia patients in complete cytogenetic remission: does achievement of a stable major molecular response at any time point identify a privileged group of patients? A multicenter experience in Argentina and UruguayCarolina Pavlovsky, Isabel Giere, Beatriz Moiraghi, et al.
Journal of Medicinal Chemistry|June 29, 2001
4-Hydroxy-5,6-dihydropyrones as inhibitors of HIV protease: the effect of heterocyclic substituents at C-6 on antiviral potency and pharmacokinetic parametersS E Hagen, J Domagala, C Gajda, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 16, 2023
Long-Term Follow-Up in Patients With Chronic Myeloid Leukemia Treated With Ponatinib in a Real-World Cohort: Safety and Efficacy AnalysisMaría José Mela Osorio, Beatriz Moiraghi, María Victoria Osycka, et al.
Bioorganic & Medicinal Chemistry|September 1, 1996
Discovery and optimization of nonpeptide HIV-1 protease inhibitorsP J Tummino, J V Prasad, D Ferguson, et al.
British Journal of Haematology|October 6, 2004
Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the 'cutaneous variant'Andrés J M Ferreri, Elías Campo, John F Seymour, et al.
Journal of Medicinal Chemistry|November 26, 1997
4-hydroxy-5,6-dihydropyrones. 2. Potent non-peptide inhibitors of HIV proteaseB D Tait, S Hagen, J Domagala, et al.
Leukemia & Lymphoma|August 9, 2020
Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphomaGraeme A M Fraser, Asher Chanan-Khan, Fatih Demirkan, et al.
Leukemia|October 14, 2018
Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphomaG Fraser, P Cramer, F Demirkan, et al.
Pageof 8